FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161298450> ?p ?o ?g. }

• W3161298450 endingPage "3273" @default.
• W3161298450 startingPage "3258" @default.
• W3161298450 abstract "Dysregulated adenosine-to-inosine (A-to-I) RNA editing is implicated in various cancers. However, no available RNA editing inhibitors have so far been developed to inhibit cancer-associated RNA editing events. Here, we decipher the RNA secondary structure of antizyme inhibitor 1 (AZIN1), one of the best-studied A-to-I editing targets in cancer, by locating its editing site complementary sequence (ECS) at the 3′ end of exon 12. Chemically modified antisense oligonucleotides (ASOs) that target the editing region of AZIN1 caused a substantial exon 11 skipping, whereas ECS-targeting ASOs effectively abolished AZIN1 editing without affecting splicing and translation. We demonstrate that complete 2′-O-methyl (2′-O-Me) sugar ring modification in combination with partial phosphorothioate (PS) backbone modification may be an optimal chemistry for editing inhibition. ASO3.2, which targets the ECS, specifically inhibits cancer cell viability in vitro and tumor incidence and growth in xenograft models. Our results demonstrate that this AZIN1-targeting, ASO-based therapeutics may be applicable to a wide range of tumor types. Dysregulated adenosine-to-inosine (A-to-I) RNA editing is implicated in various cancers. However, no available RNA editing inhibitors have so far been developed to inhibit cancer-associated RNA editing events. Here, we decipher the RNA secondary structure of antizyme inhibitor 1 (AZIN1), one of the best-studied A-to-I editing targets in cancer, by locating its editing site complementary sequence (ECS) at the 3′ end of exon 12. Chemically modified antisense oligonucleotides (ASOs) that target the editing region of AZIN1 caused a substantial exon 11 skipping, whereas ECS-targeting ASOs effectively abolished AZIN1 editing without affecting splicing and translation. We demonstrate that complete 2′-O-methyl (2′-O-Me) sugar ring modification in combination with partial phosphorothioate (PS) backbone modification may be an optimal chemistry for editing inhibition. ASO3.2, which targets the ECS, specifically inhibits cancer cell viability in vitro and tumor incidence and growth in xenograft models. Our results demonstrate that this AZIN1-targeting, ASO-based therapeutics may be applicable to a wide range of tumor types." @default.
• W3161298450 created "2021-05-24" @default.
• W3161298450 creator A5001857515 @default.
• W3161298450 creator A5011769510 @default.
• W3161298450 creator A5013555382 @default.
• W3161298450 creator A5014039845 @default.
• W3161298450 creator A5017426783 @default.
• W3161298450 creator A5021695333 @default.
• W3161298450 creator A5025099280 @default.
• W3161298450 creator A5028905834 @default.
• W3161298450 creator A5032467527 @default.
• W3161298450 creator A5033204736 @default.
• W3161298450 creator A5035730112 @default.
• W3161298450 creator A5035873423 @default.
• W3161298450 creator A5039250073 @default.
• W3161298450 creator A5043469891 @default.
• W3161298450 creator A5045067652 @default.
• W3161298450 creator A5046309150 @default.
• W3161298450 creator A5049637756 @default.
• W3161298450 creator A5052281306 @default.
• W3161298450 creator A5057894271 @default.
• W3161298450 creator A5063532843 @default.
• W3161298450 creator A5082650313 @default.
• W3161298450 creator A5085466660 @default.
• W3161298450 creator A5089241007 @default.
• W3161298450 date "2021-11-01" @default.
• W3161298450 modified "2023-10-14" @default.
• W3161298450 title "Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer" @default.
• W3161298450 cites W1547213195 @default.
• W3161298450 cites W1875625635 @default.
• W3161298450 cites W1986272738 @default.
• W3161298450 cites W1999361121 @default.
• W3161298450 cites W2004590033 @default.
• W3161298450 cites W2016916936 @default.
• W3161298450 cites W2022192230 @default.
• W3161298450 cites W2026303899 @default.
• W3161298450 cites W2041676007 @default.
• W3161298450 cites W2042478629 @default.
• W3161298450 cites W2050191240 @default.
• W3161298450 cites W2051010056 @default.
• W3161298450 cites W2052722906 @default.
• W3161298450 cites W2054086992 @default.
• W3161298450 cites W2061657172 @default.
• W3161298450 cites W2071230707 @default.
• W3161298450 cites W2074562954 @default.
• W3161298450 cites W2075781213 @default.
• W3161298450 cites W2079377204 @default.
• W3161298450 cites W2080418767 @default.
• W3161298450 cites W2086241605 @default.
• W3161298450 cites W2086561953 @default.
• W3161298450 cites W2098645655 @default.
• W3161298450 cites W2108230228 @default.
• W3161298450 cites W2115221577 @default.
• W3161298450 cites W2127626827 @default.
• W3161298450 cites W2128719162 @default.
• W3161298450 cites W2133798407 @default.
• W3161298450 cites W2138825103 @default.
• W3161298450 cites W2144134250 @default.
• W3161298450 cites W2154495644 @default.
• W3161298450 cites W2155611036 @default.
• W3161298450 cites W2156538352 @default.
• W3161298450 cites W2168639664 @default.
• W3161298450 cites W2170498465 @default.
• W3161298450 cites W2173666904 @default.
• W3161298450 cites W2323793261 @default.
• W3161298450 cites W2462382383 @default.
• W3161298450 cites W2517866739 @default.
• W3161298450 cites W2587731662 @default.
• W3161298450 cites W2630192492 @default.
• W3161298450 cites W2750951626 @default.
• W3161298450 cites W2757211226 @default.
• W3161298450 cites W2770323050 @default.
• W3161298450 cites W2803902474 @default.
• W3161298450 cites W2808067587 @default.
• W3161298450 cites W2809076434 @default.
• W3161298450 cites W2885863338 @default.
• W3161298450 cites W3043492381 @default.
• W3161298450 cites W3131515933 @default.
• W3161298450 doi "https://doi.org/10.1016/j.ymthe.2021.05.008" @default.
• W3161298450 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8571177" @default.
• W3161298450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33974998" @default.
• W3161298450 hasPublicationYear "2021" @default.
• W3161298450 type Work @default.
• W3161298450 sameAs 3161298450 @default.
• W3161298450 citedByCount "6" @default.
• W3161298450 countsByYear W31612984502022 @default.
• W3161298450 countsByYear W31612984502023 @default.
• W3161298450 crossrefType "journal-article" @default.
• W3161298450 hasAuthorship W3161298450A5001857515 @default.
• W3161298450 hasAuthorship W3161298450A5011769510 @default.
• W3161298450 hasAuthorship W3161298450A5013555382 @default.
• W3161298450 hasAuthorship W3161298450A5014039845 @default.
• W3161298450 hasAuthorship W3161298450A5017426783 @default.
• W3161298450 hasAuthorship W3161298450A5021695333 @default.
• W3161298450 hasAuthorship W3161298450A5025099280 @default.
• W3161298450 hasAuthorship W3161298450A5028905834 @default.
• W3161298450 hasAuthorship W3161298450A5032467527 @default.
• W3161298450 hasAuthorship W3161298450A5033204736 @default.

• next